OAR Statement on the Use of Hydroxychloroquine (HCQ) and Chloroquine (CQ) During the Pandemic
posted: August 3, 2020
In response to the drug shortage which began in March, OAR expressed concern about the availability of treatments for patients currently taking HCQ and CQ and whether access would be restricted as a result of the Federal Food and Drug Administration (FDA) Emergency Use Authorization (EUA). OAR submitted a position statement to several local news sources to share a rheumatology perspective and used social media to share this information.
Read OAR’s Statement on HCQ and CQ
On June 15, the FDA revoked its EUA of HCQ and CQ for the treatment of Covid-19. The agency determined that HCQ and CQ do not meet the statutory criteria for EUA based upon the most current scientific evidence available on the drugs’ potential benefits and risks for treating or preventing infection.